Spotlight On
β For high-risk patients, classic "watch and wait" may cede to early therapy
Latest in Spotlight On
PCPs are "perfectly situated" to identify initial thinking changes of patients, expert says
HER2 blockade, PARP inhibitors, and other novel strategies
Not all patients are candidates for delandistrogene moxeparvovec
Emerging targets and treatment pathways in multiple myeloma
Not all patients are candidates for delandistrogene moxeparvovec
Emerging targets and treatment pathways in multiple myeloma
More in Spotlight On
Young MS patients are at risk of irreversible disability accrual
Other JAK inhibitors, combinations, and novel therapies offer more hope for patients
Molecular testing is beginning to make a difference for patients
GLP-1 receptor agonists may be able to tackle the major modifiable risk factor
Earlier diagnosis may lead to improved long-term outcomes
Despite benefits, rotavirus vaccine uptake lags behind other childhood vaccines
Could quintuplet therapy be next?
As approved products move to earlier use, novel approaches aim to improve responses after relapse
The search for widely accepted measures continues
The procedure offers a potential cure, but comes with a risk of early morbidity and mortality
Two assessments suggest more investment is needed
Delayed diagnoses remain a problem nationwide
